Total
0
Shares
InnoCan - Founder and CEO, Iris Bincovich - The Market Herald Canada
Founder and CEO, Iris Bincovich
Source: The Investor Coliseum
  • InnoCan Pharma (INNO) has received the FDA’s Technical Validation and Approval for marketing its Relief & Go pain relief spray
  • The approval will specifically allow the company to start marketing the product in the United States of America
  • InnoCan’s flagship over-the-counter spray provides short-term relief for joint and muscle pain
  • Reports suggest that the global market for chronic pain treatment will reach over C$143 billion by 2024
  • InnoCan Pharma (INNO) is up 5.13 per cent and is currently trading at 20 cents per share

InnoCan Pharma (INNO) has received the FDA’s Technical Validation and Approval for marketing its Relief & Go pain relief spray.

The approval from the Food and Drug Administration specifically allows the company to market the product in the United States. 

InnoCan’s Relief & Go pain relief spray is the first product of the company’s Derma CBD product line to be manufactured. It is designed to provide short-term relief for joint pain, and to target pain in the muscles. 

The over-the-counter, flagship spray contains magnesium oil, methyl salicylate, menthol, and CBD. The magnesium acts as a muscle relaxant, the CBD is anti-inflammation, and the menthol component is an analgesic.  

In addition to a spray, the formulation can also be administered through roll-on or lotion formats.

InnoCan’s co-founder and CEO, Iris Bincovich, commented on the news of the FDA approval.

“We are excited to receive the approval from the FDA to market our flagship pain relief product in the USA. 

“This represents the company’s ability to develop and practice breakthrough technologies to create new CBD-based products for the growing pain relief market,” she said.

According to the American Academy of Pain Medicine, chronic pain affects approximately 1.5 billion people around the worldwide. In a global population of approximately 7.8 billion people, this represents roughly 19.2 per cent of people on Earth. 

Research conducted by Prescient & Strategic Intelligence suggested that the global market for chronic pain treatment could reach approximately C$143 billion by 2024. 

InnoCan Pharma (INNO) is up 5.13 per cent and is trading at 20 cents per share, as of 1:10pm EDT.


Subscribe


More From The Market Herald
MediPharm Labs - Asia Pacific CEO, Warren Everitt - The Market Herald Canada

" MediPharm Labs (TSX:LABS) spirals with major slide in revenue

Shares in MediPharm Labs (LABS) have taken a major hit today after the company reported an 88 per cent drop in year-over-year revenue.
Aurora Cannabis Inc. - Founder, Terry Booth - The Market Herald Canada

" Tailspin continues for Aurora Cannabis (TSX:ACB)

Shares in Aurora Cannabis (ACB) have taken another double-digit dive today as the once promising Canadian cannabis bubble continues to deflate.
SLANG Worldwide Inc - CEO, Chris Driessen - The Market Herald Canada

" SLANG Worldwide (CSE:SLNG) debuts on the OTCQB

Cannabis packaging company SLANG Worldwide (SLNG) has commenced trading on the OTCQB, hoping to expand its trading presence in the US.
Radient Technologies Inc. - President & CEO Denis Taschuk - The Market Herald Canada

" Radient Technologies (TSXV:RTI) marks milestone shipment

Cannabis company, Radient Technologies (RTI) has successfully completed its first shipment of products to the BC Liquor Distribution Branch.